MX2015015144A - Potenciador de inhibidores del homologo de zeste. - Google Patents
Potenciador de inhibidores del homologo de zeste.Info
- Publication number
- MX2015015144A MX2015015144A MX2015015144A MX2015015144A MX2015015144A MX 2015015144 A MX2015015144 A MX 2015015144A MX 2015015144 A MX2015015144 A MX 2015015144A MX 2015015144 A MX2015015144 A MX 2015015144A MX 2015015144 A MX2015015144 A MX 2015015144A
- Authority
- MX
- Mexico
- Prior art keywords
- enhancer
- inhibitors
- zeste homolog
- zeste
- homolog
- Prior art date
Links
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 title abstract 3
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817436P | 2013-04-30 | 2013-04-30 | |
| US201361842038P | 2013-07-02 | 2013-07-02 | |
| US201361907024P | 2013-11-21 | 2013-11-21 | |
| US201461936460P | 2014-02-06 | 2014-02-06 | |
| PCT/IB2014/061012 WO2014177982A1 (en) | 2013-04-30 | 2014-04-25 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015015144A true MX2015015144A (es) | 2016-02-18 |
Family
ID=50877537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015144A MX2015015144A (es) | 2013-04-30 | 2014-04-25 | Potenciador de inhibidores del homologo de zeste. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9505745B2 (enExample) |
| EP (1) | EP2991980B1 (enExample) |
| JP (1) | JP6373973B2 (enExample) |
| KR (1) | KR20160003115A (enExample) |
| CN (1) | CN105308038B (enExample) |
| AU (1) | AU2014261075B2 (enExample) |
| BR (1) | BR112015027527A2 (enExample) |
| CA (1) | CA2910873A1 (enExample) |
| CL (1) | CL2015003200A1 (enExample) |
| DO (1) | DOP2015000270A (enExample) |
| EA (1) | EA030196B1 (enExample) |
| ES (1) | ES2717680T3 (enExample) |
| HK (1) | HK1214815A1 (enExample) |
| MX (1) | MX2015015144A (enExample) |
| NZ (1) | NZ630205A (enExample) |
| PE (1) | PE20151981A1 (enExample) |
| PH (1) | PH12015502414A1 (enExample) |
| SG (1) | SG11201508203TA (enExample) |
| WO (1) | WO2014177982A1 (enExample) |
| ZA (1) | ZA201507398B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2812001B1 (en) * | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| BR112015008447A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | métodos para tratar câncer |
| CA2910873A1 (en) * | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| JP2016523955A (ja) | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
| HRP20241145T1 (hr) | 2014-02-06 | 2024-11-22 | Nxera Pharma Uk Limited | Biciklički aza spojevi kao agonisti muskarinskih receptora |
| KR20170068603A (ko) * | 2014-10-28 | 2017-06-19 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| EP3370725A4 (en) * | 2015-11-06 | 2019-07-03 | Epizyme, Inc. | PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR |
| HRP20192209T1 (hr) | 2015-11-19 | 2020-07-24 | Jiangsu Hengrui Medicine Co., Ltd. | Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini |
| WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US20170337814A1 (en) * | 2016-05-20 | 2017-11-23 | Donald Edward Morgan | Safety alerting drivers device and system |
| KR102351782B1 (ko) | 2016-09-07 | 2022-01-17 | 상하이 하이헤 파마수티컬 컴퍼니 리미티드 | 피리도 5원 방향족 고리계 화합물, 이의 제조 방법 및 용도 |
| WO2018125983A1 (en) | 2016-12-30 | 2018-07-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| FI4043466T3 (fi) | 2018-01-31 | 2024-10-30 | Mirati Therapeutics Inc | Prc2:n estäjiä |
| CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| BR112021024131A2 (pt) * | 2019-05-31 | 2022-01-11 | Haisco Pharmaceuticals Pte Ltd | Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo |
| WO2020247475A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| CN110964200A (zh) * | 2019-12-19 | 2020-04-07 | 新纳奇材料科技江苏有限公司 | 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法 |
| CN114787143A (zh) * | 2019-12-23 | 2022-07-22 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007519753A (ja) * | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| CN1989131A (zh) * | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| SG178273A1 (en) * | 2009-08-07 | 2012-03-29 | Merck Patent Gmbh | Novel azaheterocyclic compounds |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| HRP20170736T1 (hr) | 2010-05-07 | 2017-07-28 | Glaxosmithkline Llc | Indoli |
| ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CN103987842A (zh) * | 2011-09-30 | 2014-08-13 | 葛兰素史密斯克莱有限责任公司 | 治疗癌症的方法 |
| EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| PL3184523T3 (pl) | 2012-04-13 | 2019-12-31 | Epizyme Inc | Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2910873A1 (en) * | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
-
2014
- 2014-04-25 CA CA2910873A patent/CA2910873A1/en not_active Abandoned
- 2014-04-25 PE PE2015002298A patent/PE20151981A1/es not_active Application Discontinuation
- 2014-04-25 AU AU2014261075A patent/AU2014261075B2/en not_active Ceased
- 2014-04-25 WO PCT/IB2014/061012 patent/WO2014177982A1/en not_active Ceased
- 2014-04-25 HK HK16102708.1A patent/HK1214815A1/zh unknown
- 2014-04-25 CN CN201480033093.6A patent/CN105308038B/zh not_active Expired - Fee Related
- 2014-04-25 EP EP14727619.0A patent/EP2991980B1/en active Active
- 2014-04-25 KR KR1020157033651A patent/KR20160003115A/ko not_active Ceased
- 2014-04-25 US US14/787,866 patent/US9505745B2/en not_active Expired - Fee Related
- 2014-04-25 NZ NZ630205A patent/NZ630205A/en not_active IP Right Cessation
- 2014-04-25 MX MX2015015144A patent/MX2015015144A/es unknown
- 2014-04-25 ES ES14727619T patent/ES2717680T3/es active Active
- 2014-04-25 JP JP2016511152A patent/JP6373973B2/ja not_active Expired - Fee Related
- 2014-04-25 BR BR112015027527A patent/BR112015027527A2/pt not_active IP Right Cessation
- 2014-04-25 EA EA201592068A patent/EA030196B1/ru not_active IP Right Cessation
- 2014-04-25 SG SG11201508203TA patent/SG11201508203TA/en unknown
-
2015
- 2015-10-06 ZA ZA2015/07398A patent/ZA201507398B/en unknown
- 2015-10-19 PH PH12015502414A patent/PH12015502414A1/en unknown
- 2015-10-30 CL CL2015003200A patent/CL2015003200A1/es unknown
- 2015-10-30 DO DO2015000270A patent/DOP2015000270A/es unknown
-
2016
- 2016-10-13 US US15/292,200 patent/US9790212B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6373973B2 (ja) | 2018-08-15 |
| WO2014177982A1 (en) | 2014-11-06 |
| US20160102083A1 (en) | 2016-04-14 |
| CN105308038B (zh) | 2018-05-29 |
| EP2991980B1 (en) | 2019-01-02 |
| EA030196B1 (ru) | 2018-07-31 |
| ZA201507398B (en) | 2017-01-25 |
| PH12015502414A1 (en) | 2016-02-22 |
| CN105308038A (zh) | 2016-02-03 |
| DOP2015000270A (es) | 2016-02-15 |
| AU2014261075B2 (en) | 2017-01-19 |
| SG11201508203TA (en) | 2015-11-27 |
| BR112015027527A2 (pt) | 2017-07-25 |
| JP2016517878A (ja) | 2016-06-20 |
| ES2717680T3 (es) | 2019-06-24 |
| CL2015003200A1 (es) | 2016-04-22 |
| EA201592068A1 (ru) | 2016-05-31 |
| KR20160003115A (ko) | 2016-01-08 |
| CA2910873A1 (en) | 2014-11-06 |
| HK1214815A1 (zh) | 2016-08-05 |
| US9790212B2 (en) | 2017-10-17 |
| PE20151981A1 (es) | 2016-01-14 |
| AU2014261075A1 (en) | 2015-11-05 |
| NZ630205A (en) | 2017-03-31 |
| EP2991980A1 (en) | 2016-03-09 |
| US9505745B2 (en) | 2016-11-29 |
| US20170029412A1 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| WO2013173441A3 (en) | Enhancer of zeste homolog 2 inhibitors | |
| MX2015006152A (es) | Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m. | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| PH12017501921A1 (en) | Novel compounds | |
| PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| PH12015502615B1 (en) | Chemical compounds | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| TW201613864A (en) | Novel compounds | |
| MX369952B (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. | |
| PH12018500446A1 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| MX2016014559A (es) | Compuestos para el tratamiento de cancer. | |
| MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
| EA201790604A1 (ru) | Ингибиторы гистондеметилазы | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general |